← Leaderboards
Robert Brown
University Of North Carolina Chapel Hill
$2,236,004
Attributed
$2,236,004
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$2,236,004 · 2
By mechanism
M01$2,236,004 · 2
Top collaborators
No co-investigators on record.
Most similar at University Of North Carolina Chapel Hill
Same institution · by research overlap
- Charles Michael Van Der Horst$17,688,631
- Michael W Fried$8,954,521
- Michael J Fried$0
- Robert S Brown$3,426,728
- Angela D Kashuba$21,136,729
Others in their field
Top investigators on “Liver Disorder Chemotherapy”
- David Heimbrook · Leidos Biomedical Research, Inc.$31,285,017
- Steven H. Belle · University Of Pittsburgh At Pittsburgh$7,828,252
- Larry Arthur$7,554,000
- Carlos O Esquivel · Stanford University$6,293,124
- Linda G. Griffith · Massachusetts Institute Of Technology$4,716,039
- M. Celeste Simon · University Of Pennsylvania$4,690,953
Research focus
Liver Disorder ChemotherapyClinical ResearchHuman SubjectHuman Therapy EvaluationAntiviral AgentsDrug Screening /EvaluationHepatitis BNucleoside AnalogOral AdministrationPharmacokineticsReverse Transcriptase InhibitorsChronic Disease /DisorderMicroorganism Disease ChemotherapyRibavirinRelapse /RecurrenceHepatitis C VirusHepatitis CCombination ChemotherapyInterferon Alpha
Grant awards (10)
RETREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WITH INTRON A$190,747
M01 · FY2002 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$190,747
M01 · FY2002 · RR
RETREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WITH INTRON A$294,555
M01 · FY2001 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$294,555
M01 · FY2001 · RR
RETREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WITH INTRON A$190,747
M01 · FY2001 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$190,747
M01 · FY2001 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$294,555
M01 · FY2000 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$294,555
M01 · FY2000 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$294,555
M01 · FY2000 · RR
PHARMACOKINETICS STUDY OF ORAL LOBUCAVIR$241
M01 · FY2000 · RR